Trial Profile

An Open-Label Comparison of the Efficacy and Safety of the Low-Molecular-Weight Heparin [certoparin sodium] (3000 U Anti-Xa Once Daily) With Unfractionated Heparin for the Prevention of Thromboembolic Complications in Acutely Ill Non-Surgical Patients.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Dec 2010 Results published in the Expert Opinion on Pharmacotherapy.
11 Jul 2009 Results presented at the 22nd Congress of the International Society on Thrombosis and Haemostasis.
03 Nov 2008 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com